利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.017 秒)

    Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
    5.
    发明申请
    Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease 审中-公开
    使用能够抑制信号素的蛋白水解加工的化合物用于预防，治疗，诊断和预后的侵袭性疾病

    公开(公告)号：US20070010433A1

    公开(公告)日：2007-01-11

    申请号：US10520741

    申请日：2003-07-10

    申请人： Morten Albrechtsen ,  Claus Christensen ,  Eugene Lukanidin ,  Ole Olsen

    发明人： Morten Albrechtsen ,  Claus Christensen ,  Eugene Lukanidin ,  Ole Olsen

    IPC分类号： A61K38/17

    CPC分类号： C07K14/4703 ,  A61K38/00 ,  C07K16/18 ,  G01N33/57484 ,  G01N33/57488 ,  G01N2333/4704

    摘要： The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment diagnosis and/or prognosis of an invasive disease. The invention features the compounds selected from the group comprising antisense compounds derived from the sequence of SEMA3E and/or sema3E, peptide compounds derived from the sequence of said semaphorins, anti-bodies against said semaphorins, and peptide compounds derived from the sequence of Plexin A receptor. Furthermore, the invention provides methods for prognosis and/diagnosis of malignancy of cancer based of estimation of the levels of expression and proteolytic processing of said semaphorins in a sample of a tissue or body fluid. The invention also concerns a method for producing an attractant polypeptide by establishing a cleavage product of SEMA3E. and/or sema3E.

    摘要翻译： 本发明涉及用于抑制表达和/或蛋白水解处理信号素SEMA3E和/或sema3E和/或通过所述信号素的蛋白水解产物激活受体的化合物在制备用于预防，治疗诊断和/ 或侵入性疾病的预后。 本发明的特征在于选自衍生自SEMA3E和/或sema3E序列的反义化合物的组合物，衍生自所述信号素序列的肽化合物，针对所述信号素的抗体，以及衍生自Plexin A序列的肽化合物 受体。 此外，本发明基于对组织或体液样品中所述信号素的表达水平和蛋白水解加工的估计，提供了对癌症恶性程度的预后和/诊断方法。 本发明还涉及通过建立SEMA3E的切割产物来产生引诱多肽的方法。 和/或sema3E。

    Methods for treating cancer
    6.
    发明授权
    Methods for treating cancer 失效
    治疗癌症的方法

    公开(公告)号：US06638504B1

    公开(公告)日：2003-10-28

    申请号：US09298625

    申请日：1999-04-23

    申请人： Eugene Lukanidin

    发明人： Eugene Lukanidin

    IPC分类号： C07K1600

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K47/6851 ,  A61K2039/505 ,  B60R2021/23538 ,  C07K14/4728 ,  C07K16/30 ,  C07K2317/73 ,  C07K2319/00 ,  C12N2799/026

    摘要： The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 MRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as tseful model systems for in vitro and in vivo anti-metastasis drug screening.

    摘要翻译： 本发明涉及通过检测由mts-1基因编码的mts-1 MRNA或mts-1蛋白来诊断恶性肿瘤。 本发明考虑使用针对mts-1蛋白的重组mts-1 DNA和抗体来诊断几种类型的肿瘤细胞（包括例如甲状腺，上皮，肺，肝和肾）肿瘤细胞的转移潜能。 本发明还涉及哺乳动物细胞系和具有高和低转移潜力的肿瘤，其被开发用作用于体外和体内抗转移药物筛选的棘手模型系统。